Patent ID: 7704497
Filing Date: 2010-04-27
Classification: A61K,A61P,C07K,Y10S

Abstract:
1. A modified IgG, comprising a human IgG constant domain comprising one or more amino acid substitutions relative to a wild-type human IgG constant domain at one or more of amino acid residues 252, 254, 256, 309, 311, 433 or 434, numbered according to the EU index as in Kabat, wherein the one or more amino acid substitutions is a tyrosine, phenylalanine, serine, tryptophan or threonine amino acid substitution at amino acid residue 252; a threonine amino acid substitution at amino acid residue 254; a serine, arginine, glutamine, glutamic acid or aspartic acid amino acid substitution at amino acid residue 256; a proline amino acid substitution at amino acid residue 309; a serine, glutamic acid or leucine amino acid substitution at amino acid residue 311; an arginine, serine, isoleucine, proline or glutamine amino acid substitution at amino acid residue 433; or a histidine, phenylalanine or tyrosine amino acid substitution at amino acid residue 434; wherein the modified IgG has an increased half-life compared to the half-life of an IgG having the wild-type human IgG constant domain, and wherein the modified IgG immunospecifically binds to tumor necrosis factor (TNF).